

Le Cannabis pour prévenir l'athérosclérose ?

François Mach, MD,
Service de Cardiologie
Département de Médecine Interne
Hôpital Universitaire de Genève
Francois.Mach@medecine.unige.ch

www.cardiology-geneva.ch

Genève, le 26 juillet 2005

Pathophysiology of atherosclerosis

REVIEW ARTICLE




MECHANISMS OF DISEASE




Inflammation, Atherosclerosis, and Coronary Artery Disease

Göran K. Hansson, M.D., Ph.D.

N Engl J Med April 21 2005;352:1685

Pathophysiology of atherosclerosis






Δ^9 -tetrahydrocannabinol (THC)

The endocannabinoid system


⇒ 2 cannabinoid receptors + endogenous ligands




Receptors:

CB1: central and peripheral nervous system

CB2: on immune cells




The endocannabinoid system



Cannabis has a treatment for

- Anorexia
- Vomitting

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor



T cell co-stimulation assay with peritoneal macrophages from wildtype^{+/+} or CB2^{-/-} mice

Cannabinoids as therapeutic agents ?

Rheumatoid arthritis:


The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Malfait AM et al. *PNAS* 2000;97:9561

Multiple sclerosis:


Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis

Lyman WD et al. *J Neuroimmunol* 1989;23:73




**Does THC treatment have
anti-atherosclerotic effects ?**


The cannabinoid receptor CB2 is expressed within human and mouse atherosclerotic plaques




human coronary plaque




mouse aortic root plaque




mouse aortic arch plaque



mouse normal carotid artery




mouse spleen




CB 2^{-/-} mouse spleen


The cannabinoid receptor CB2 is expressed on macrophages and T lymphocytes within mouse atherosclerotic plaques




MΦ/DAPI




CB2




MΦ/CB2



CD4/DAPI




CB2




CD4/CB2


Experimental protocol




- > delta-9-Tetrahydrocannabinol (**THC**)
- > daily oral administration of 1 mg per kg THC in high fat milk



THC treatment reduces atherosclerotic plaque development




Reduced relative macrophage content in THC-treated mice




Oral administration of 1 mg kg⁻¹ THC (daily dose)

The CB2 receptor antagonist SR144528 abolishes the anti-atherosclerotic effect of THC





Oral administration of 1 mg kg^{-1} THC (daily dose)


THC reduces proliferative responses and inhibits TH1 polarization



THC reduces migration capacity of peritoneal macrophages in vitro



THC reduces CCR2 expression on splenocytes in vitro



Real Time PCR analysis of stimulated splenocytes from ApoE^{-/-} mice

Cannabinoids as therapeutic agents ?

letters to nature

.....

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

**Sabine Steffens¹, Niels R. Veillard^{1*}, Claire Arnaud^{1*}, Graziano Pelli¹,
Fabienne Burger¹, Christian Staub³, Andreas Zimmer⁴,
Jean-Louis Frossard² & François Mach¹**

¹*Division of Cardiology, Department of Medicine, Foundation for Medical Research,*

²*Division of Gastroenterology and* ³*Institute of Legal Medicine, University Hospital, Faculty of Medicine, 1211 Geneva, Switzerland*

⁴*Laboratory for Molecular Neurobiology, Department of Psychiatry, University of Bonn, 53105 Bonn, Germany*

* These authors contributed equally to this work

Cannabinoids as therapeutic agents ?

news and views


Pharmacology

Marijuana and your heart

Michael D. Roth

Marijuana smoke can have harmful effects on the heart. But one of its active components may ease inflammation and slow the progression of coronary artery disease.

Cannabinoids as therapeutic agents ?



Acknowledgements

**Cardiology Division
Medicine Department
Geneva University Hospital**

Sabine Steffens
Graziano Pelli
Fabienne Burger
Niels Veillard
Claire Arnaud

Gastroenterology Division

Jean-Louis Frossard

**Department of Pathology,
Geneva University**

Marie-Luce Bochaton-Piallat

Swiss National Research Found

NovImmune S.A. Geneva

Marie Kosco-Vilbois

**Institute of Legal Medicine
Geneva University**

Christian Staub

**Laboratory for Molecular Neurobiology
Bonn University, Germany**

Andreas Zimmer, Meliha Karsak

European Vascular Genomics Network

www.evgn.org

